AzTrials
AzTrials

Severe Acute MalnutritionNCT06308848

Microbiota Directed Food for Children With Severe Acute Malnutrition

A study testing Microbiota-Directed Food and Ready-to-Use Therapeutic Food in people with Severe Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Severe acute malnutrition (SAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Read more about this study

Who is it for?
Ages 6 to 24 months
Conditions the study is for
Severe Acute Malnutrition
What is being tested?
Microbiota-Directed Food and Ready-to-Use Therapeutic Food
Could I receive a placebo?
No, everyone receives an active treatment
How many people
256 participants
Where
1 siteBangladesh
Study dates
15 Apr 2024to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 24 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • The trial will include SAM children of either sex without any medical complication
  • Children aged between 6-<24 months and with MUAC <115 mm and/or WLZ <-3

Who cannot join

  • Children are not suffering from SAM.
  • Children with bi-pedal oedema.
  • Failed to obtain consent for study participation from parents or legal guardian.
  • Suffering from any chronic illness(es) or having severe anemia (< 8 g/dl).
  • History of using antibiotics in the past seven days.
  • Children participating in other food intervention programs.
  • Children having known history of soy, peanut or milk protein allergy.
  • Children who will not pass appetite test.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Md Hasan Hafizur Rahman, MPH, MBBS contact

01813333444

hasan.hafizur@icddrb.org

Ishita Mostafa, BDS, MPH contact

01755512359

ishita.mostafa@icddrb.org

Bangladesh1 site
  • Kurigram Study site

    Kurigrām

    Md Hasan Hafizur Rahman, MPH, MBBS, 01813333444, hasan.hafizur@icddrb.org

Other trials in Bangladesh

About this study

Official title: Proof-of-Concept Study for a Microbiota-Directed Food in Children With Uncomplicated Severe Acute Malnutrition in Rural Bangladesh

Severe acute malnutrition (SAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing SAM is crucial to prevent its progression to other childhood morbidity and mortality and to ensure healthy child development. To meet the nutritional requirement of SAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use therapeutic food. The investigators propose this proof-of-concept trial to establish evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with SAM in comparison to the standard RUTF.

Read the detailed description

Burden: As per Global Nutrition report 2021, 45.4 million children under the age of 5 years were reported to be wasted. Asia is a home to more than three-quarters of all these children suffering from wasting. According to Bangladesh Multiple Indicator Cluster Survey 2019 around 10% under 5 children were wasted, while 2.3% suffered from severe form of wasting also known as severe acute malnutrition (SAM). SAM is defined by the World Health Organization (WHO) as weight-for-length Z score (WLZ) of less than -3 and/or presence of bilateral pedal edema and/or a mid-upper arm circumference less than 115 mm.

SAM children are found to be suffering from relative gut microbial immaturity, which is related to their growth faltering. Ready-to-use therapeutic food (RUTF) is a key component of the treatment protocol for SAM children and is widely used throughout the world. Which however is found to be partially effective or ineffective in repairing the gut microbial immaturity present in SAM children. To combat this, affordable therapeutic food formulation is needed that can be used to treat acute malnutrition in children with the potential to restore gut microbial colony related to growth and early childhood development.

Knowledge gap: Researchers at icddr,b in collaboration with Washington University in St. Louis has developed a Microbiota-Directed Complementary Food (MDCF) formulation (based on locally available food ingredients) that has the potential of repairing the gut microbiota of children with malnutrition. Results from a recently conducted study of MDCF on Bangladeshi children suffering from moderate acute malnutrition (MAM) showed that the children who received the food exhibited significantly faster rates of ponderal growth compared to those treated with a standard ready-to-use supplementary food. Early evidence, however, is limited to a small sample of children with MAM. This leaves a paucity of data on the role of microbiota directed food interventions on the nutritional as well as microbial recovery and proteomic improvement in children with SAM.

Relevance: To meet the nutritional requirement of SAM children, researchers have come up with a novel intervention named Microbiota-Directed Food (MDF), a ready-to-use therapeutic food by modifying the original MDCF recipe to meet the nutritional requirement of SAM children as well as to make it align with the existing WHO/UNICEF specifications for a nutritional intervention for treating acute malnutrition. The proposed formulation MDF with a relatively lower calorie content will improve the nutritional status by modulating and improving the gut microbial dysbiosis that is present in SAM children. Therefore, the investigators propose this POC trial to generate evidence on the effect of the novel intervention on the ponderal growth, microbial and proteomic recovery among the children with SAM in comparison to the standard RUTF.

Hypothesis: The locally developed MDF would be proven beneficial in nutritional recovery, repairing gut microbiota and restoring plasma biomarkers of healthy growth when compared to standard RUTF among children suffering from SAM.

Primary Objective:

  • To assess the role of MDF in improving the weight-for-length Z score (WLZ) of SAM children

Secondary Objectives:

  • To investigate the effect of MDF in repairing the gut microbiota of SAM children
  • To monitor the change produced by MDF in rebalancing the body composition of the SAM children towards a more appropriate lean-to-fat mass ratio present in SAM children
  • To explore the impact of MDF in restoring plasma biomarkers of healthy growth
  • To measure the efficacy of MDF in improving the Weight-for-Age Z-score (WAZ) in children with SAM
  • To measure the efficacy of MDF in improving the Length-for-Age Z-score (LAZ) in children with SAM
  • To assess the acceptability of the MDF among SAM children
  • To measure the intake of the MDF by SAM children

Study design:

This will be a double blinded, parallel-group, simple randomized controlled trial.

Study site:

This study will be conducted among residents of Kurigram district. Kurigram District is situated in Northwest Bangladesh (Rangpur Division).

Randomization:

At enrolment, children will be randomized into one of the two intervention arms using permuted block randomization method to ensure even distribution across the intervention arms over time.

Recruitment, Screening and Consenting:

Census, screening, enrolment of study participants will be done in Kurigram. Initially 6-<24 months old children will be screened by the study health workers through community surveillance by measurement of MUAC (measuring weight and length/height where possible) of the children. Parents of eligible children who meet the inclusion criterion will be approached about enrolment into the study. A trained Field Research Assistant will explain the study in detail, answer any questions from the parent(s), and invite the parent(s) to enroll the child in the study. After acquiring consent from the parents, at the beginning of the study, the child along with his parents will be invited to the study clinic where initial anthropometric assessment (weight, length, MUAC) will be done, and they will be assessed further for eligibility by the study medical personnel regarding any concurrent illness. If found eligible an appetite test will be performed among these children. For the appetite test, standard RUTF will be offered to each child. If a child had a body weight of <4 kg, then she/he will be offered an amount of 11.5 g, 23 g will be offered if body weight is between 4 and 9.9 kg, 46 g if between 10 and 14.9 kg and 69 g for those ≥15 kg. A child will be considered to have passed the appetite test if she/he consume the required amount according to his/her body weight within 45 minutes. If a child passes the appetite test, then he or she will be considered for enrolment into the study. Our rationale behind the use of 45 minutes as the duration for the appetite test was based on previously published articles.

If the child passes the appetite test, our study research assistant will sought additional information from the parents on the demographic characteristics (families' wealth, standard of housing, family structure and parental characteristics etc.), household food insecurity (HFIAS), vaccination status of the children.

Intervention delivery and feeding:

The study design comprises a 3-month period of nutritional intervention and 12-month post-intervention follow-up. The recommended nutrition for the SAM children is about 150-200 Kcal/kg/day including breast feeding. As the care providers will encourage the study children to receive the diet while continuing to receive their usual diet, the investigators therefore have set the target intake to be 175 kcal/kg/day as per national and international guidelines. Every child will be provided an appropriate amount of the therapeutic diet (~500kCal/92g sachet) based on their weight from the day of enrolment. Interventions are iso-caloric.

Both the study interventions will be delivered to the homes of participants by project staff on a weekly basis as sachet versions will be produced by a food manufacturing industry. The mother, or the main caregiver will feed the participant at home. The mother/primary caregiver will be instructed to feed the child directly from the sachet. If the child doesn't feel comfortable consuming directly from sachet, they can also spoon or use properly washed hands to feed the diets to their children until s/he refuses to eat. Children will be considered as refusing further intake if they move their head away from the food, cry, clamp the mouth or clinch the teeth, or become agitated, spit out the food or refuse to swallow. Once the child refuses to take, mothers/caregivers will be counselled to give a pause and then try after some time.

Mother/caregiver will be properly trained to monitor their child for any possible side effects/adverse events (e.g., rash, urticaria due to food allergy or any significant changes in clinical status). And if any side effects/adverse events are observed, they will be advised to contact study team immediately. Additionally, the enrolled children will be monitored and caregivers will also be asked every week by trained Field Research Assistants for any illness/side effects/adverse events (e.g., increases in diarrhoea, flatulence, vomiting, skin rash or urticaria due to food allergy or any significant changes in clinical status). If any side effects/adverse events are observed, then they will receive standard care at the nearest health facility or other higher centre if required.

At each weekly food delivery visit, all used and unused food packets from previous week will be collected for weighing in order to estimate intake during the period. In addition, study personnel will ask mothers/caregivers to rate their child's liking of the supplement on 7-point Hedonic scale. A score of 7, will be ranked as 'like extremely' and the lowest value 1 will be ranked as 'dislike extremely'. Hedonic scale data will be collected one week after the initiation of the intervention.

Morbidity data will be collected weekly during the intervention period and bi-weekly during the first three months of the follow-up period.

The Caregiver Reported Early Development Instruments (CREDI) long form will be evaluated for all the children at enrollment, at the end of intervention and three months after finishing intervention.

Food frequency questionnaires (FFQ) will be completed at enrolment, prior to randomization and monthly during the entire intervention period and during the first three months of the follow-up period and three monthly during the rest of the period in order to assess nutrient intake.

Anthropometry:

Anthropometric assessment will be performed by trained study personnel at enrolment, every two weeks interval during the intervention phase and then monthly for the first three months of the follow up period and then at three monthly for the rest of the period until end of the study.

Body composition analysis:

Bioelectrical Impedance Analysis (BIA) is a method of assessing the body composition by measuring the body fat in relation to lean body mass. BIA will be used to measure total fat and fat free at the beginning, at the end of intervention and three months after completing intervention.

Faecal sample collection:

1-2 gm of faecal material will be collected from each child at enrolment, monthly during the intervention period, at the end of intervention and at 4, 5, 6, 9, 12th month during the follow-up period and the end of study.

Blood sample collection:

2 mL of blood samples will be collected from every SAM child at enrolment and just after the intervention is completed and at the 9th month during follow up period and at the end of the study.

Oral swab collection:

Oral swab samples will be collected by using a commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.

Standard care All participants will receive standard care at enrolment and throughout the period of the study, including screening for common illnesses and routine medications, as per the national protocol. Standard treatment for community management of severe acute malnutrition as per national guideline. Treatment for all indicated conditions will be provided as per IMCI guidelines and the national protocol free of charge. All concomitant treatments will be recorded in the appropriate study case report form (CRF).

All caregivers will receive basic nutritional and general health counselling at each visit. Caregivers will be provided with information regarding acute malnutrition as well as the benefits of treatment.

Being tested
Microbiota-Directed Food, Ready-to-Use Therapeutic Food
Keywords
Microbiota directed food, SAM, Gut microbiota, Bangladesh
Medical subject headings
Severe Acute Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Microbiota-Directed FoodDietary supplement

    Also called MDF

    MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.

  • Ready-to-Use Therapeutic FoodDietary supplement

    Also called RUTF

    RUTF is standard ready-to-use therapeutic food for SAM children aged 6 months and above.

Study groups in NCT06308848
Study groupRoleWhat they receive
Microbiota Directed Food (MDF)ExperimentalEach participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
Receives: Dietary Supplement: Microbiota-Directed Food
Ready-to-Use Therapeutic Food (RUTF)Active comparatorEach participant will receive 12 weeks of RUTF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
Receives: Dietary Supplement: Ready-to-Use Therapeutic Food

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean change in Weight-for-Length Z-score (WLZ)

    In this study, nutritional status will be assessed through anthropometric measurement at enrolment, every two weeks interval during the intervention phase and then monthly for the first three months of the follow up period and then at three monthly for the rest of the period until end of the study.

    Measured: Baseline to 12 weeks of intervention followed by 12 months of follow-up

Secondary outcomes (5)
  1. Gut microbial community repair

    Non-diarrheal stool samples will be collected at enrolment, monthly during the intervention period, at the end of intervention and at 4, 5, 6, 9, 12th month during the follow-up period and the end of study from all the participants for assessment of the composition of gut microbiota and features of the microbiome.

    Oral swab samples will be collected by using a commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.

    Measured: Baseline to 12 weeks of intervention followed by 12 months of follow-up

  2. Improvement in the levels of plasma protein biomarkers of healthy growth

    Blood samples will be collected at enrolment and just after the intervention is completed and at the 9th month during follow up period and at the end of the study.

    Non-diarrheal stool samples will be collected at enrolment, monthly during the intervention period, at the end of intervention and at 4, 5, 6, 9, 12th month during the follow-up period and the end of study from all the participants for measuring biomarkers of gut inflammation.

    Measured: Baseline to 12 weeks of intervention followed by 12 months of follow-up

  3. Mean change in Weight-for-Age Z-score (WAZ)

    In this study, nutritional status will be assessed through anthropometric measurement at enrolment, every two weeks interval during the intervention phase and then monthly for the first three months of the follow up period and then at three monthly for the rest of the period until end of the study.

    Measured: Baseline to 12 weeks of intervention followed by 12 months of follow-up

  4. Mean change in Length-for-Age Z-score (LAZ)

    In this study, nutritional status will be assessed through anthropometric measurement at enrolment, every two weeks interval during the intervention phase and then monthly for the first three months of the follow up period and then at three monthly for the rest of the period until end of the study.

    Measured: Baseline to 12 weeks of intervention followed by 12 months of follow-up

  5. Mean change in body composition (% body fat mass and % fat-free mass)

    In this study, nutritional status will be also assessed through Bioelectrical impedance at the beginning, at the end of intervention and three months after completing intervention.

    Measured: Baseline to 12 weeks of intervention followed by 3 months of follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2024
  2. Study start15 Apr 2024 (estimated)
  3. Primary completion31 Oct 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled trial (Proof of concept study)
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
256 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06308848
Sponsor's protocol ID
PR-22077
Status last verified
Feb 2024
First submitted
5 Mar 2024
Last updated
13 Mar 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Microbiota-Directed Food and Ready-to-Use Therapeutic Food in people with Severe Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 13 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Md Hasan Hafizur Rahman, MPH, MBBS (01813333444, hasan.hafizur@icddrb.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean change in Weight-for-Length Z-score (WLZ) (time frame: Baseline to 12 weeks of intervention followed by 12 months of follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in